Affimed NV (NASDAQ:AFMD)’s share price was down 11.1% on Friday . The company traded as low as $2.53 and last traded at $2.57, approximately 2,433,867 shares traded hands during mid-day trading. An increase of 235% from the average daily volume of 726,686 shares. The stock had previously closed at $2.89.
A number of analysts have weighed in on AFMD shares. ValuEngine upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Zacks Investment Research lowered shares of Affimed from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $6.36.
The company’s 50 day moving average price is $2.96 and its 200-day moving average price is $3.03. The stock has a market cap of $190.91 million, a P/E ratio of -6.76 and a beta of 2.91. The company has a quick ratio of 3.47, a current ratio of 3.48 and a debt-to-equity ratio of 0.02.
Hedge funds have recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D bought a new position in shares of Affimed during the second quarter valued at $29,000. Parametric Portfolio Associates LLC bought a new position in shares of Affimed during the second quarter valued at $41,000. Meeder Asset Management Inc. bought a new position in shares of Affimed during the third quarter valued at $47,000. Mackenzie Financial Corp bought a new position in shares of Affimed during the second quarter valued at $47,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Affimed during the second quarter valued at $47,000. 51.01% of the stock is owned by hedge funds and other institutional investors.
Affimed Company Profile (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Further Reading: What is the Moving Average Convergence Divergence (MACD) oscillator?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.